Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2 |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qRT-PCR, Western blot analysis ect. |
| Sample | HCC tumor tissues |
| Expression Pattern | up-regulated |
| Function Description | H19 as one of the most upregulated long noncoding RNA (lncRNA) in association with Tgfbr2 inactivation in TICs. Tgfbr2 inactivation by Ad-Cre led to a 5-fold increase of H19 expression in TICs. Accordingly, TGF-B treatment reduced H19 expression.low level of H19 mRNA expression in human HCC tissues from patients with the epithelial TGF-B gene signature in association with favorable prognosis. |
| Pubmed ID | 30014520 |
| Year | 2018 |
| Title | A novel TGF-? and H19 signaling axis in tumor-initiating hepatocytes that regulates hepatic carcinogenesis. |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |